Spectrum Pharmaceuticals, Inc. Announces Third Quarter 2009 Corporate Update; ZEVALIN(R) Sales up 80% over Third Quarter 2008

IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.

MORE ON THIS TOPIC